A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Active, not recruiting · NCT05286229 · Registry updated 2025-08-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2025-08-08 | NCT05286229 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duplicate_Okayama Medical Center /ID# 240949 | Okayama | Japan | 1 |
| Hokkaido University Hospital /ID# 242672 | Sapporo | Japan | 1 |
| Kanazawa University Hospital /ID# 240948 | Kanazawa | Japan | 1 |
| National Cancer Center Hospital East /ID# 240943 | Kashiwa-shi | Japan | 1 |
| The University of Osaka Hospital /ID# 242032 | Suita-shi | Japan | 1 |
| Yamagata University Hospital /ID# 240945 | Yamagata | Japan | 1 |